Compositions and methods for synthesizing 5′-capped RNAs
Provided herein are methods and compositions for synthesizing 5′Capped RNAs wherein the initiating capped oligonucleotide primers have the general form m7 Gppp[N 2′Ome ] n [N] m wherein m7 G is N7-methylated guanosine or any guanosine analog, N is any natural, modified or unnatural nucleoside, “n” can be any integer from 0 to 4 and “m” can be an integer from 1 to 9.
1. A compound of the following formula:
or a salt thereof, wherein:
B 1 and B 2 are each independently an unprotected nucleoside base;
R 1 is CH 3 ; and
R 2 is H or CH 3 .
2. The compound of claim 1 , wherein B 1 is a naturally occurring nucleoside base;
and wherein B 2 is a naturally occurring nucleoside base.
3. The compound of claim 2 , wherein B 1 is a naturally occurring purine ring; and
wherein B 2 is a naturally occurring purine ring.
4. The compound of claim 3 , wherein B 1 is selected from the group consisting of adenine, guanine, and N 6 -methyladenine; and wherein B 2 is selected from the group consisting of adenine, guanine, and N 6 -methyladenine.
5. The compound of claim 1 , wherein B 1 is selected from the group consisting of adenine, guanine, and N 6 -methyladenine.
6. The compound of claim 1 , wherein B 2 is selected from the group consisting of adenine, guanine, and N 6 -methyladenine.
7. The compound of claim 1 , wherein R 2 is CH 3 .
8. The compound of claim 2 , wherein R 2 is CH 3 .
9. The compound of claim 3 , wherein R 2 is CH 3 .
10. The compound of claim 4 , wherein R 2 is CH 3 .
11. The compound of claim 5 , wherein R 2 is CH 3 .
12. The compound of claim 6 , wherein R 2 is CH 3 .
13. An RNA molecule comprising the compound of claim 1 .
14. An isolated cell comprising an RNA molecule according to claim 13 .
15. A pharmaceutical composition comprising an RNA molecule according to claim 13 and a pharmaceutically acceptable carrier.
16. A pharmaceutical composition comprising a cell comprising an RNA molecule according to claim 13 .